Anglo-Swedish drugs firm AstraZeneca said Thursday it will buy Bristol-Myers Squibb's stake in their diabetes venture for up to $4.1 billion (3.0 billion euros).
"AstraZeneca today announced an agreement under which AstraZeneca will acquire the entirety of Bristol-Myers Squibb's interests in the companies' diabetes alliance for an initial consideration of $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments," it said in a statement.
"AstraZeneca has also agreed to pay various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments up to $225 million when certain assets are subsequently transferred."
Following completion of the transaction, AstraZeneca will own intellectual property and global rights for the development, manufacture and commercialization of the diabetes business.
"Together with Bristol-Myers Squibb we concluded that consolidating ownership of the diabetes portfolio would benefit both companies and allow us to better serve the needs of diabetic patients," said AstraZeneca chief executive Pascal Soriot.
"Today's announcement reinforces AstraZeneca's long-term commitment to diabetes, a core strategic area for us and an important platform for returning AstraZeneca to growth."
London-listed AstraZeneca added that diabetes was a key focus for the company, particularly in emerging markets.
"Diabetes is rapidly becoming a global challenge of epidemic proportions that is expected to affect more than 550 million people by 2030," Soriot said.
"Much of this impact will be felt in emerging markets where AstraZeneca has a strong presence.
"In recent years we've worked with our alliance partners at Bristol-Myers Squibb to develop an innovative portfolio of non-insulin anti-diabetic medicines that help address the needs of these patients."
Explore further: AstraZeneca buys US cancer drugs firm
© 2013 AFP
Medical Xpress on facebook
Related Stories
Bristol-Myers to buy diabetes drug maker for $5B
Jul 01, 2012
(AP) — Drug maker Bristol-Myers Squibb Co. says it agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash.
EU OKs Bristol-Myers, AstraZeneca diabetes drug
Nov 14, 2012
(AP)—Drugmakers Bristol-Myers Squibb Co. and AstraZeneca PLC say their experimental diabetes pill has gotten its first major approval, in the European Union.
AstraZeneca buys US cancer drugs firm
Aug 27, 2013
AstraZeneca said on Tuesday that it has agreed to buy US-based cancer drugs company Amplimmune, as the Anglo-Swedish pharmaceuticals group seeks to bolster its flagging pipeline of new products.
Experimental diabetes drug makes comeback
Dec 12, 2013
A panel of federal health advisers has backed the benefits of an experimental diabetes drug that uses a new method to reduce blood sugar, setting aside previous concerns about the pill's safety.
AstraZeneca settles legal dispute with Watson (Update)
Mar 25, 2013
(AP)—Anglo-Swedish pharmaceutical company AstraZeneca has settled a patent dispute with Watson Laboratories, Inc., removing a threat against its top-selling cholesterol-control drug, Crestor.
Recommended for you
Vemurafenib: Result unchanged despite new data
16 hours ago
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed vemurafenib (trade name: Zelboraf), a drug for the treatment ...
Japan to seek criminal prosecution of Novartis
Dec 18, 2013
Japan's health ministry intends to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged fabrication of drugs data, a report said Wednesday.
Pfizer, Teva reach deal to allow generic Viagra
Dec 17, 2013
Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.
GSK to scrap individual sales targets (Update)
Dec 17, 2013
British drug company GlaxoSmithKline said Tuesday it would stop paying doctors to promote its products at speaking engagements and scrap individual sales targets, months after its ethics were challenged by a bribery scandal ...
New concerns over safety of common anesthetic
Dec 13, 2013
Patients receiving the widely used anesthesia drug etomidate for surgery may be at increased risk or mortality and cardiovascular events, according to a study in the December issue of Anesthesia & Analgesia, official journa ...
Experimental diabetes drug makes comeback
Dec 12, 2013
A panel of federal health advisers has backed the benefits of an experimental diabetes drug that uses a new method to reduce blood sugar, setting aside previous concerns about the pill's safety.
User comments
© Medical Xpress 2011-2013, Science X network
Anglo-Swedish drugs firm AstraZeneca said Thursday it will buy Bristol-Myers Squibb's stake in their diabetes venture for up to $4.1 billion (3.0 billion euros).
"AstraZeneca today announced an agreement under which AstraZeneca will acquire the entirety of Bristol-Myers Squibb's interests in the companies' diabetes alliance for an initial consideration of $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments," it said in a statement.
"AstraZeneca has also agreed to pay various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments up to $225 million when certain assets are subsequently transferred."
Following completion of the transaction, AstraZeneca will own intellectual property and global rights for the development, manufacture and commercialization of the diabetes business.
"Together with Bristol-Myers Squibb we concluded that consolidating ownership of the diabetes portfolio would benefit both companies and allow us to better serve the needs of diabetic patients," said AstraZeneca chief executive Pascal Soriot.
"Today's announcement reinforces AstraZeneca's long-term commitment to diabetes, a core strategic area for us and an important platform for returning AstraZeneca to growth."
London-listed AstraZeneca added that diabetes was a key focus for the company, particularly in emerging markets.
"Diabetes is rapidly becoming a global challenge of epidemic proportions that is expected to affect more than 550 million people by 2030," Soriot said.
"Much of this impact will be felt in emerging markets where AstraZeneca has a strong presence.
"In recent years we've worked with our alliance partners at Bristol-Myers Squibb to develop an innovative portfolio of non-insulin anti-diabetic medicines that help address the needs of these patients."
Explore further: AstraZeneca buys US cancer drugs firm
© 2013 AFP
Medical Xpress on facebook
Related Stories
Bristol-Myers to buy diabetes drug maker for $5B
Jul 01, 2012
(AP) — Drug maker Bristol-Myers Squibb Co. says it agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash.
EU OKs Bristol-Myers, AstraZeneca diabetes drug
Nov 14, 2012
(AP)—Drugmakers Bristol-Myers Squibb Co. and AstraZeneca PLC say their experimental diabetes pill has gotten its first major approval, in the European Union.
AstraZeneca buys US cancer drugs firm
Aug 27, 2013
AstraZeneca said on Tuesday that it has agreed to buy US-based cancer drugs company Amplimmune, as the Anglo-Swedish pharmaceuticals group seeks to bolster its flagging pipeline of new products.
Experimental diabetes drug makes comeback
Dec 12, 2013
A panel of federal health advisers has backed the benefits of an experimental diabetes drug that uses a new method to reduce blood sugar, setting aside previous concerns about the pill's safety.
AstraZeneca settles legal dispute with Watson (Update)
Mar 25, 2013
(AP)—Anglo-Swedish pharmaceutical company AstraZeneca has settled a patent dispute with Watson Laboratories, Inc., removing a threat against its top-selling cholesterol-control drug, Crestor.
Recommended for you
Vemurafenib: Result unchanged despite new data
16 hours ago
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed vemurafenib (trade name: Zelboraf), a drug for the treatment ...
Japan to seek criminal prosecution of Novartis
Dec 18, 2013
Japan's health ministry intends to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged fabrication of drugs data, a report said Wednesday.
Pfizer, Teva reach deal to allow generic Viagra
Dec 17, 2013
Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.
GSK to scrap individual sales targets (Update)
Dec 17, 2013
British drug company GlaxoSmithKline said Tuesday it would stop paying doctors to promote its products at speaking engagements and scrap individual sales targets, months after its ethics were challenged by a bribery scandal ...
New concerns over safety of common anesthetic
Dec 13, 2013
Patients receiving the widely used anesthesia drug etomidate for surgery may be at increased risk or mortality and cardiovascular events, according to a study in the December issue of Anesthesia & Analgesia, official journa ...
Experimental diabetes drug makes comeback
Dec 12, 2013
A panel of federal health advisers has backed the benefits of an experimental diabetes drug that uses a new method to reduce blood sugar, setting aside previous concerns about the pill's safety.
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment